Research and development expenses were USD 9.2 million, against USD 6.4 million in the third quarter of 2025. General and administrative expenses were USD 2.4 million, against USD 2.6 million. Operating loss was USD 11.6 million, against USD 9.0 million, and other income, net, …
Chief Executive Officer Paul Carreiro said the company's new execution focus was starting to show results, with new customers committing to its solutions across retail and consumer packaged goods. He said the commercialLeadershipteam is mostly in place and that the focus is turning this …
Net income was USD 31.8 million, and capital expenditures were USD 13.8 million. Adjusted EBITDA was USD 58.2 million, with a margin of 18.9%, up 200 basis points.
The increase in third-quarter revenue came mainly from higher direct-to-consumer sales. For the nine months, revenue was USD 16.1 million, down 6.2% from USD 17.1 million, because of non-recurring revenue from a pharmaceutical partner recognized in the prior-year period, partly offset by growth from …
Eikon describes itself as a late-stage clinical biopharmaceutical company building a global, integrated organization to develop medicines for serious unmet medical needs. Its approach combines traditional biology research with advanced engineering.
Research and development expenses were USD 17.8 million, against USD 15.0 million a year earlier. General and administrative expenses were USD 3.9 million, against USD 4.1 million. Total operating expenses were USD 21.7 million, against USD 19.1 million, and loss from operations was USD …
Revenue was USD 3.3 million, against USD 17.7 million in the second quarter. The company said second-quarter revenue was driven primarily by the inaugural Enhanced Games held in May, while third-quarter revenue reflects the acceleration of Live Enhanced telehealth sales and continued recognition under …
GAAPDiluted Earnings per Sharefrom continuing operations were USD 0.23, compared with USD 0.26 a year earlier. Results exclude the Feminine Care business, which is reported as discontinued operations. President and chief executive Rod Little said fiscal 2026 brought progress and change, with growth in …
Research and development expenses were USD 2.5 million, against USD 1.3 million a year earlier. General and administrative expenses were USD 2.6 million, against USD 3.3 million. Total operating expenses were USD 5.0 million, against USD 4.6 million, and the loss from operations was …
Research and development expenses were USD 47.2 million for the three months ended September 30, 2026, against USD 22.5 million a year earlier. The filing states the USD 24.7 million increase was primarily driven by USD 15.3 million in clinical trial, preclinical study and …